I am sorry to hear of your loss. It is good that you are aware of the important things in life and that money is not everything.
FTT as a shell is, IMO, as good as they come. As the directors are not taking a salary, pipeline is on hold and existing trial costs will cease, the burn on this will be low. The cash should last some time and they may also get a decent amount of R&D refund back.
It will also be in the board's best interest to find a deal reasonably quickly so they are not going unpaid for too long. So I would hold as this could recover depending on the deal, back to a $10m+ market cap on initial euphoria.
- Forums
- ASX - By Stock
- DLM
- Ann: Results of Phase 2 Clinical Trial
Ann: Results of Phase 2 Clinical Trial, page-84
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online